CapitaLand Ascendas REIT: A Mixed View (OTCMKTS:ACDSF)

tobiasjo/iStock via Getty Images Elevator Pitch CapitaLand Ascendas REIT (OTCPK:ACDSF) [A17U:SP] is rated as a Hold. My earlier November 28, 2023 update touched on the divergence in the performance of CapitaLand Ascendas REIT’s different assets and the REIT’s inorganic growth strategy. In this latest write-up, I draw attention to ACDSF’s Q1 2024 business update, and…

Read More

James Hardie Industries: Mixed Housing Outlook And A Lack Of Margin Of Safety (NYSE:JHX)

VIKTOR FEDORENKO/iStock via Getty Images Synopsis James Hardie Industries (NYSE:JHX) specializes in the production and sale of fiber cement and fiber gypsum building solutions. JHX’s last three years financial results have shown consistent net sales growth. In addition, it was able to maintain its margins throughout the same period by focusing on selling higher-margin products…

Read More

Jamf Holding: Above-Expectations Earnings Overshadowed By Mixed Guidance (NASDAQ:JAMF)

napong rattanaraktiya/iStock via Getty Images Elevator Pitch Jamf Holding Corp. (NASDAQ:JAMF) stock is rated as a Hold. Previously, I evaluated Jamf’s financial performance for the third quarter of the prior year with my November 9, 2023 initiation article. I draw attention to JAMF’s latest quarterly results and its outlook in the current write-up. Jamf’s Q4…

Read More

GMS Inc Stock: Mixed Q2 Results Keep Us On The Fence (NYSE:GMS)

FluxFactory GMS Inc (NYSE:GMS) recently reported its latest quarterly results, with revenue and EPS coming in above expectations. The company recognized as a leading manufacturer of wallboard, ceilings, and steal-framing installations has benefited from the resilient construction activity despite the volatile macro backdrop over the past year. Indeed, the stock is up more than 40%…

Read More

X4: Dip Following Mixed Results In Chronic Neutropenia Indication Worth Buying (NASDAQ:XFOR)

Md Babul Hosen Brief summary of prior coverage X4 Pharmaceuticals (NASDAQ:XFOR) is developing mavorixafor for WHIM (a rare inherited form of chronic neutropenia), as well as for a broader chronic neutropenia patient population. Mavorixafor’s mechanism of action is ideal for WHIM and results from clinical trials are very convincing for an eventual approval in WHIM….

Read More

Small Business Sentiment Mixed Under The Hood

deepblue4you The NFIB unveiled its latest look at small business sentiment early Tuesday morning. The headline number remains in the bottom decile of its historical range, falling 0.1 points to 90.6 in November. That is compared to expectations which called for the number to be unchanged last month. Across the categories factoring into the index,…

Read More

Travel + Leisure: Despite Mixed Results, Significant Recurrent Revenue And Growth

Igor Vershinsky/iStock via Getty Images Travel + Leisure Co. (NYSE:TNL) recently delivered mixed quarterly results, but the company continues to deliver quarterly net sales growth and adjusted EBITDA growth. In my view, the significant amount of recurrent revenue, recent dividend growth, and the potential of the network effects established with brands and hotels will most…

Read More

MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis (MOR)

tonaquatic Thesis overview MorphoSys AG (NASDAQ:MOR) recently announced positive topline results from its phase 3 trial of pelabresib in myelofibrosis (MF). The study easily met the primary endpoint. However, despite the strong positive trend, statistical significance was not achieved at key secondary endpoints assessing symptomatic improvement. Nevertheless, in a pre-specified subgroup analysis in intermediate-risk patients…

Read More

Flash PMIs Mixed | Seeking Alpha

DKosig Predicting the direction of the US or global economy has always been a humbling profession, but doing it in the post-Covid economy where monetary and fiscal activity has gone into ‘Ludicrous’ mode only makes an impossible job even harder. The latest releases of global flash PMI readings for November from S&P Global only add…

Read More

Futu Holdings Stock: Mixed Results (NASDAQ:FUTU)

Asia-Pacific Images Studio/E+ via Getty Images Elevator Pitch My rating for Futu Holdings Limited (NASDAQ:FUTU) shares is a Hold. I previously touched on the regulatory developments associated with FUTU’s business operations in my prior March 9, 2023 update. In this latest article, my focus is on the review of Futu Holdings’ financial results for the…

Read More

WSB Catalyst Watch: Walmart, Target’s Mixed Signals

PixelsEffect Listen below or on the go on Apple Podcasts and Spotify Catalyst watch for the week of November 19. Seeking Alpha Senior Executive Editor Kim Khan on the quiet economic calendar. (00:21) Julie Morgan shares the latest analysis on two companies set to report earnings, Baidu, Inc. (BIDU) and Nvidia Corporation (NVDA). (02:20) They…

Read More

Amazon: Mixed Bag Ahead – Investors Beware (NASDAQ:AMZN)

Imagesrouges We previously covered Amazon.com, Inc. (NASDAQ:AMZN) in August 2023, discussing its turnaround story from the FY2022 debacle, when the e-commerce company reported negative profit margins. The combination of its drastic cost optimization efforts, returning advertising spend, and AWS’s outperformance in the FQ2’23 quarter had led to our Buy rating, further aided by the booming…

Read More

Dynavax: Analyzing Mixed Signals, Closer Look At Heplisav-B (NASDAQ:DVAX)

PepeLaguarda/iStock via Getty Images At a Glance Building on my previous analysis of Dynavax Technologies (NASDAQ:DVAX), the landscape has shifted subtly. HEPLISAV-B sales continue to be a bright spot, but new elements like insider selling activities have entered the equation. Financially, the picture remains complex: revenues have declined year-over-year, yet the rise in HEPLISAV-B sales,…

Read More

AZZ: Low Valuation But Mixed Prospects And High Leverage (NYSE:AZZ)

RossHelen/iStock via Getty Images Investment Thesis While AZZ Inc.’s (NYSE:AZZ) valuation is not expensive, it faces headwinds from the tough macroeconomic environment which is slowing some of its end-markets including commercial and residential construction, transportation, and HVAC. The company’s high debt levels and the high interest rate it is paying on its variable debt should…

Read More

Viridian Therapeutics: Mixed Bag, Not Eye-Catching Enough (NASDAQ:VRDN)

GizemBDR/iStock via Getty Images Introduction Viridian Therapeutics (NASDAQ:VRDN) is a biopharmaceutical firm committed to creating best-in-class medicines for rare and serious illnesses, specifically where existing treatments fall short. The company’s lead program, VRDN-001, a monoclonal antibody that inhibits insulin-like growth factor-1 receptor (IGF-1R), targets thyroid eye disease [TED] and has shown encouraging clinical proof-of-concept. Viridian…

Read More

CarMax: Mixed Outlook And Unattractive Valuation (NYSE:KMX)

Brandon Bell Investment Thesis CarMax, Inc.’s (NYSE:KMX) revenue growth is expected to remain under pressure in the near term due to adverse macroeconomic conditions which is resulting in lower demand for used vehicles as a result of tight discretionary spending in an inflationary environment and rising interest rates. Moreover, the easing of supply issues in…

Read More

IWB: Mixed Picture On Economy

da-kuk The iShares Russell 1000 ETF (NYSEARCA:IWB) is a tech-focused slice of the US stock market with plenty of large-cap exposure. Ultimately, these stocks are all high multiple and their valuations are being driven by cash flows forecast way into the distance. That means a lot of sensitivity to the interest and inflation rate situation,…

Read More

Danone: Q2 Earnings, A Mixed Serving Of Profits And Challenges (OTCMKTS:DANOY)

Vladimirs_Gorelovs Thesis My article analyzes Danone S.A.’s (OTCQX:DANOY) Q2 2023 Earnings Report, noting the company’s impressive sales growth and ongoing improvements in their transformation plan. However, I also shed light on potential risk factors and headwinds such as negative volume mix impacts from adverse foreign exchange rates as well as challenges with Russia that ultimately…

Read More